Wren Therapeutics is commercialising Cambridge and Lund research into therapies for protein misfolding diseases, which include Alzheimer's and motor neurone disease.
Wren Therapeutics, a UK-based small molecule and antibody treatment developer spun out of University of Cambridge and Lund University, closed a £18m ($23.3m) series A round today led by hedge fund Baupost Group. Venture capital firm LifeForce Ventures and multiple unnamed private investors also took part in the round. Founded in 2016, Wren Therapeutics is…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
